title: [The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
abstract: The possibility was studied of using the native beta-adrenoblocking agent anaprilin for prolonged control of the level of portal hypertension in liver cirrhosis. It was established that anaprilin (dose: 40 mg daily) reduces the level of portal hypertension and increases the efficacy of treatment of liver cirrhosis associated with ascites and esophageal-gastric bleeding. A therapeutic effect was achieved in most patients (67 of 75).
authors.forename: I P
authors.initials: IP
authors.lastname: Bondarenko
authors.forename: A A
authors.initials: AA
authors.lastname: Dubinskiĭ
authors.forename: I G
authors.initials: IG
authors.lastname: Tereshkin
mesh_terms: D000328:Adult; D000368:Aged; D001201:Ascites / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004341:Drug Evaluation; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*
chemical_list: D011433:Propranolol
vernacular_title: Primenenie anaprilina dlia korrektsii portal'noĭ gipertenzii pri tsirroze pecheni.